IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
Cassandra L MoyerAmanda LanierJing QianDarian ColemanJamal L HillVidyasagar VuligondaMartin E SandersAbhijit MazumdarPowel H BrownPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.